Browse our anti-Coagulation Factor III (thromboplastin, Tissue Factor) (F3) Antibodies

Mouse (Murine) Coagulation Factor III (thromboplastin, Tissue Factor) (F3) interaction partners

1. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. Ticagrelor reduced TNF-alpha (show TNF Antibodies)-induced TF expression via proteasomal degradation.

2. Macrophage tissue factor prothrombotic activity is regulated by integrin-alpha4/arf6 (show ARF6 Antibodies) trafficking.

3. Evening primrose oil and forskolin decreased the prothrombotic effect of celecoxib initiated by a LPS (show TLR4 Antibodies) challenge in mice, and this effect was, at least partly, mediated by mitigating TF expression and activity.

4. Thrombin (show F2 Antibodies)-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease.

5. These findings reveal a novel biological function and mechanism of the protein C (show PROC Antibodies) pathway in which protein S and the aPC (show APC Antibodies)-cleaved form of fV are cofactors for anti-inflammatory cell signaling by aPC (show APC Antibodies) in the context of endotoxemia and infection

6. Lung epithelial tissue factor regulates alveolar procoagulant activity and permeability in acute lung injury.

7. PGE2 increases both TF expression and activity through the regulation of the EP1 (show PTGER1 Antibodies)/SIRT1 (show SIRT1 Antibodies) pathway.

8. Fas (show FAS Antibodies)-initiated, caspase-3 (show CASP3 Antibodies)-dependent hepatocyte apoptosis increases tissue factor procoagulant activity through a mechanism involving phosphatidylserine externalization.

9. Heme promotes tissue factor-dependent coagulation activation and induces tissue factor expression on leukocytes in vivo.

10. TF is essential for the development of pericyte coverage of tumor microvessels and aPL (show FASL Antibodies)-induced tumor cell expression of chemokine ligand 2 (show CXCL2 Antibodies), a mediator of pericyte recruitment

Human Coagulation Factor III (thromboplastin, Tissue Factor) (F3) interaction partners

1. The proinflammatory cytokine IL-33 (show IL33 Antibodies) induces differential tissue factor expression and activity in monocyte subsets, as well as the release of procoagulant microvesicless. In this manner, IL-33 (show IL33 Antibodies) may contribute to the formation of a prothrombotic state characteristic for cardiovascular disease.

2. Pin1 (show PIN1 Antibodies) is a fast-acting enzyme which may be utilised by cells to protect the phosphorylation state of TF in activated cells prolonging TF activity and release, and therefore ensuring adequate haemostasis.

3. Circulating pentraxin nCRP has little pro-angiogenic effect but when dissociated into mCRP on the surface of endothelial cells it is able to trigger potent proangiogenic effects by inducing F3-gene upregulation and TF signaling.

4. In the presence of tissue factor-positive cancer cells, the CAR-modified T cells (TF-CAR T) were highly activated and showed specific cytotoxicity to TF-positive cancer cells.

5. TF is an angiogenic-specific receptor and the target molecule for fVII (show F7 Antibodies)-targeted therapeutics.

6. It was demonstrated that the nature of the clot (show TXNDC17 Antibodies) formed, as determined from the quartz crystal microbalance parameters, was highly dependent on the rate of clot (show TXNDC17 Antibodies) formation resulting from the TF concentration used for activation. These parameters could also be related to physical clot (show TXNDC17 Antibodies) characteristics such as fibrin fibre diameter and fibre density, as determined by scanning electron microscopic image analysis.

7. Through induction of TF in vascular endothelial cells, IL-33 (show IL33 Antibodies) could enhance their thrombotic capacity and thereby might impact on thrombus formation in the setting of atherosclerosis.

8. Tissue Factor was highly expressed in 73.6 % of osteosarcoma biopsies, and expression associated significantly with disease-free survival.

9. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.

10. the identification of platelet TF and TLR4 (show TLR4 Antibodies) as regulators of the effect of E. coli O111 might represent a novel therapeutic target to reduce the devastating consequences of the hemostatic disorder during sepsis.

Rabbit Coagulation Factor III (thromboplastin, Tissue Factor) (F3) interaction partners

1. Arterial (18)F-fluorodeoxyglucose uptake reflects balloon catheter-induced thrombus formation and tissue factor expression via nuclear factor-kappaB in rabbit atherosclerotic lesions.

2. Polycations could present a new class of anticoagulants with such unique upstream downregulation of blood coagulation, selectively blocking tissue factor-dependent factor VII (show TH Antibodies) activation.

3. Upregulated TF expression and increased plasma TF level during reperfusion period, reduced plasma TFPI-1 (show TFPI Antibodies) level during reperfusion period.

4. lectin-like oxidized LDL receptor (show OLR1 Antibodies) Oxidized low-density lipoprotein receptor (show LDLR Antibodies) 1expression appears to be closely associated with tissue factor expression, apoptotic events and morphological vulnerability in atherosclerotic lesions

Pig (Porcine) Coagulation Factor III (thromboplastin, Tissue Factor) (F3) interaction partners

1. Tissue factor expression on porcine neonatal islet cell clusters is an important initiator of instant blood-mediated inflammatory reaction in islet xenotransplantation.

2. Prolonged clopidogrel treatment reduced coronary tissue factor (TF) expression and tended to reduce the blood TF level post-PCI (show SERPINA5 Antibodies), thus possibly modulating the risk of late thrombosis.

3. Procoagulant porcine tissue factor is induced in primary pig aortic endothelial cells only by fresh human plasma, and not by heat-inactivated plasma.

4. myocardial infarction induced proinflammatory gene and protein expression in peripheral blood mononuclear cells of tissue factor cyclo-oxygenase-2, monocyte chemoattractant protein-1 (show CCL2 Antibodies) and CRP (show CRP Antibodies)